Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results–Medicare Database
作者： Gunjan L. Shah , Aaron N. Winn , Pei-Jung Lin , Andreas Klein , Kellie A. Sprague
DOI: 10.1016/J.BBMT.2015.05.013
关键词:
摘要: Abstract In the past decade, number of autologous hematopoietic stem cell transplants (Auto HSCT) for older patients with multiple myeloma (MM) has increased dramatically, as cost transplantation. The cost-effectiveness this modality in over age 65 is unclear. Using Surveillance, Epidemiology, and End Results–Medicare database to create a propensity-score matched sample between 2000 2007, we compared survival those who received Auto HSCT did not undergo transplantation but survived at least 6 months after diagnosis, calculated an incremental ratio (ICER). Two hundred seventy underwent Median overall from diagnosis was significantly longer than (58 versus 37 months, P
tctjournal.org
core.ac.uk
elsevier.com参考文章(45)
Richard Cook, Economic and clinical impact of multiple myeloma to managed care. Journal of Managed Care Pharmacy. ,vol. 14, pp. 19- 25 ,(2015) , 10.18553/JMCP.2008.14.S7-A.19
Peter J Neumann, Gillian D Sanders, Louise B Russell, Joanna E Siegel, Theodore G Ganiats, None, Cost-effectiveness in health and medicine Oxford University Press. ,(1996)
Martin L. Brown, Gerald F. Riley, Nicki Schussler, Ruth Etzioni, Estimating health care costs related to cancer treatment from SEER-Medicare data. Medical Care. ,vol. 40, ,(2002) , 10.1097/00005650-200208001-00014
ARNOLD L. POTOSKY, GERALD F. RILEY, JAMES D. LUBITZ, RENEE M. MENTNECH, LARRY G. KESSLER, Potential for cancer related health services research using a linked Medicare-tumor registry database. Medical Care. ,vol. 31, pp. 732- 748 ,(1993) , 10.1097/00005650-199308000-00006
M. van Agthoven, C.M. Segeren, I. Buijt, C.A. Uyl-de Groot, B. van der Holt, H.M. Lokhorst, P. Sonneveld, A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma: a prospective randomised phase III study European Journal of Cancer. ,vol. 40, pp. 1159- 1169 ,(2004) , 10.1016/J.EJCA.2004.01.019
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Joan L. Warren, Linda C. Harlan, Jennifer Stevens, Richard F. Little, Gregory A. Abel, Multiple Myeloma Treatment Transformed: A Population-Based Study of Changes in Initial Management Approaches in the United States Journal of Clinical Oncology. ,vol. 31, pp. 1984- 1989 ,(2013) , 10.1200/JCO.2012.46.3323
Michel Attal, Jean-Luc Harousseau, Thierry Facon, François Guilhot, Chantal Doyen, Jean-Gabriel Fuzibet, Mathieu Monconduit, Cyrille Hulin, Denis Caillot, Reda Bouabdallah, Laurent Voillat, Jean-Jacques Sotto, Bernard Grosbois, Regis Bataille, Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma New England Journal of Medicine. ,vol. 349, pp. 2495- 2502 ,(2003) , 10.1056/NEJMOA032290
Alessandro Corso, Silvia Mangiacavalli, Federica Cocito, Cristiana Pascutto, Virginia Valeria Ferretti, Alessandra Pompa, Roberta Ciampichini, Lara Pochintesta, Lorenzo G. Mantovani, Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: A Cost-Effectiveness Analysis PLoS ONE. ,vol. 8, pp. e75047- ,(2013) , 10.1371/JOURNAL.PONE.0075047
K. Moeremans, L. Annemans, An update: health economics of managing multiple myeloma. European Journal of Cancer. ,vol. 42, pp. 1684- 1691 ,(2006) , 10.1016/J.EJCA.2005.11.036